关键词 | 新叶奖 |2026报名启动 生物基行业，有什么权威的奖项 ？ 由DT新材料、生物基能源与材料举办的 新叶奖创新评选（NEW LEAF AWARD） ， 是专注于生物基领域创新的 全球化、专业性、综合性奖项，致力 于挖掘、展示和表彰生物基行业的好产品、好企业。设有 创新材料奖、创新应用奖、创新行业解决方案奖、最具商业价值奖 四大奖项。截至目前，通 过产业链上下游专业的评审专家团，已有 100多项 创新生物基产品 获得新叶奖，因此被誉为 " 生物基行业的奥斯卡 "。 2026 新叶奖（第四届）评选活动 报名已经启动。并于 Bio-based 2026 第十一届生物基大会暨展览（2026年05月21日 ） 上举行颁奖典礼。 02 申报时间&流程 | 1 | 2 | 3 | ৰ | | --- | --- | --- | --- | | 2025.12.01 (启动报名) | 2026.3.16- | 2026.3.23- | 2026.5.21 | | 2026.03-13 (截止报名) | 2026.3.22 | 2026.3.27 | | | 参赛报名+提名 | 线上投票(初选) | 在线竞选 | ...

关键词 | 新叶奖 |2026报名启动 生物基行业，有什么权威的奖项 ？ 由DT新材料、生物基能源与材料举办的 新叶奖创新评选（NEW LEAF AWARD） ， 是专注于生物基领域创新的 全球化、专业性、综合性奖项，致力 于挖掘、展示和表彰生物基行业的好产品、好企业。设有 创新材料奖、创新应用奖、创新行业解决方案奖、最具商业价值奖 四大奖项。截至目前，通 过产业链上下游专业的评审专家团，已有 100多项 创新生物基产品 获得新叶奖，因此被誉为 " 生物基行业的奥斯卡 "。 2026 新叶奖（第四届）评选活动 报名已经启动。并于 Bio-based 2026 第十一届生物基大会暨展览（2026年05月21日 ） 上举行颁奖典礼。 01 设置四大奖项 创新材料奖、创新应用奖、创新行业解决方案奖、最具商业价值奖 。 02 申报时间&流程 | 1 | 2 | 3 | ৰ | | --- | --- | --- | --- | | 2025.12.01 (启动报名) | 2026.3.16- | 2026.3.23- | 2026.5.21 | | 2026.03-13 (截止报名) | 2026.3.22 | 20 ...

生物基行业，有什么权威的奖项 ？ 由DT新材料、生物基能源与材料举办的 新叶奖创新评选（NEW LEAF AWARD） ， 是专注于生物基领域创新的 全球化、专业性、综合性奖项，致力 于挖掘、展示和表彰生物基行业的好产品、好企业。设有 创新材料奖、创新应用奖、创新行业解决方案奖、最具商业价值奖 四大奖项。截至目前，通 过产业链上下游专业的评审专家团，已有 100多项 创新生物基产品 获得新叶奖，因此被誉为 " 生物基行业的奥斯卡 "。 2026 新叶奖（第四届）评选活动 报名已经启动。并于 Bio-based 2026 第十一届生物基大会暨展览（2026年05月21日 ） 上举行颁奖典礼。 关键词 | 新叶奖 |2026报名启动 01 设置四大奖项 创新材料奖、创新应用奖、创新行业解决方案奖、最具商业价值奖 。 02 申报时间&流程 2.初选、复选流程与获奖公布，以会务组通知为准； 03 评审维度 | 评审维度 | 技术创 | 应用创 | 功能性 | 魔业价 | 可持续性 | | --- | --- | --- | --- | --- | --- | | | 新性 | 新性 | | 値性 | | | 创新材料 ...

Core Viewpoint - The European Commission is set to release a new bioeconomy strategy on November 27, 2025, aimed at reducing reliance on fossil fuels and enhancing the value and processing levels of bio-based products [1] Group 1: Strategic Goals - The core objective of the strategy is to accelerate the development and application of bio-based products [1] - The strategy focuses on scaling up innovative investments, creating new markets, ensuring sustainable biomass supply, and promoting global cooperation [1] Group 2: Implications for Finland - Finland welcomes the strategy, viewing it as an opportunity for agricultural economic diversification [1] - The strategy is expected to enhance the EU's competitiveness and sustainability by simplifying regulations, accelerating authorizations, and providing technical support [1] - It also supports climate goals and strategic autonomy [1]

Core Insights - The 20th Central Committee's Fourth Plenary Session emphasizes the strategic importance of biomanufacturing as a key driver for economic transformation and high-quality development in China [1] Group 1: Strategic Importance of Biomanufacturing - Biomanufacturing is positioned as a critical sector for future economic growth, with a focus on core technology breakthroughs and the cultivation of an industrial ecosystem [1] - The approach to biomanufacturing should leverage China's unique conditions and institutional advantages, aiming for a comprehensive view of the entire industrial chain [1] Group 2: Characteristics of China's Biomanufacturing Industry - China's biomanufacturing industry showcases significant features such as integrated innovation, sustainability, and empowerment through the intersection of biotechnology and various fields [2] - The industry benefits from a complete industrial system and supply chain, allowing for effective engineering and market application of biomanufacturing technologies [2] Group 3: Challenges and Gaps - There are notable gaps in core technologies, original capabilities, and competitiveness in high-value products compared to international standards, particularly in high-end industrial enzymes and key equipment manufacturing [3] - A more systematic and forceful approach is needed to drive high-quality development in the biomanufacturing sector [3] Group 4: Recommendations for Development - Strengthening top-level design and strategic guidance is essential, including clearer long-term planning and prioritization of technology directions [3] - Establishing a collaborative innovation ecosystem that integrates industry, academia, and research institutions is crucial for overcoming challenges in transitioning from laboratory samples to industrial products [3] Group 5: Investment and Infrastructure - Diversifying investment and market mechanisms is necessary, including government funding and attracting social capital into biomanufacturing [4] - Building a robust foundation in talent and infrastructure is vital, with an emphasis on interdisciplinary talent cultivation and the establishment of major technological infrastructures [4]

Core Insights - The signing of five projects in the semiconductor sector at the Qidong Economic Development Zone marks a significant step in enhancing the region's industrial capabilities and supporting Shanghai's large semiconductor enterprises [1][3] Group 1: Industrial Development - The Qidong Economic Development Zone is positioned as a key area for the Yangtze River Delta's industrial innovation and green development, with a focus on semiconductor and biopharmaceutical industries [2][4] - The zone aims to integrate closely with Shanghai's industrial and innovation chains, leveraging its proximity to the city to attract high-quality projects [1][2] Group 2: Strategic Initiatives - Qidong has established the Qidong Life and Health Technology Park, which has already attracted over 60 pharmaceutical companies, with a high occupancy rate in its initial phases [3][4] - The park is designed to facilitate rapid commercialization of innovative drugs, providing tailored facilities for companies to quickly set up operations [3][4] Group 3: Investment and Growth Targets - The Qidong Economic Development Zone aims to achieve a high-tech industry scale of 30 billion yuan and over 130 high-tech enterprises by 2027 [5] - In the first half of the year, high-tech industry investment in the park accounted for 63.8% of total investments, significantly higher than the city average [4]

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. (Huaheng Bio) has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Bio is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology. The company has established a leading position in the industry over the past 20 years [3]. - The company is recognized as one of the most comprehensive enterprises in the commercialization of bio-based products through synthetic biology, being the first globally to industrialize the anaerobic fermentation of a series of amino acids, including L-Alanine and L-Valine. By 2024, it is projected to hold the largest market share for L-Alanine and L-Valine globally [3]. Product Portfolio - As of June 30, 2025, Huaheng Bio has established stable long-term partnerships with over 768 customers across 85 countries in Asia, Europe, and the Americas. Its main bio-based products include amino acids (primarily alanine series, L-Valine, tryptophan, arginine), vitamins (D-Calcium Pantothenate, D-Pantothenol, inositol), and other bio-based products (1,3-propanediol, succinic acid, malic acid, arbutin) [4]. - The company employs two green manufacturing technology platforms: fermentation and enzyme catalysis, focusing on microbial cell factories and enzyme-based production processes to reduce pollution, lower energy consumption, and minimize carbon footprints [4]. Market Potential - The global bio-based products market is expected to grow from $22.8 billion in 2020 to $42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6%. It is projected to further increase to $80.1 billion by 2030 and $109.1 billion by 2035, with CAGRs of 11.3% and 6.4% respectively [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this market [5]. Financial Performance - The company reported revenues of approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively. The corresponding profits for these periods were approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5][7].

Core Insights - The company, Huaheng Biological, announced an investment of 320 million yuan to establish an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" in Changfeng County, Hefei [1] - This investment aims to enhance production efficiency and product quality through advanced microbial fermentation technology and AI-driven process control [1] - The project is expected to take 36 months to complete and will be funded primarily through the company's own or self-raised funds [1] Investment Details - The total investment agreements signed by the company with the Changfeng (Shuangfeng) Economic Development Zone Management Committee in the past 12 months amount to 710 million yuan, including a previous agreement of 390 million yuan for a "AI-driven Biological Manufacturing R&D and Pilot Demonstration Base" [2] - The new project will be located at the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone [1] Technological Advancements - The investment will leverage cutting-edge technologies in synthetic biology and metabolic engineering, transitioning biological manufacturing from traditional fermentation to precision and intelligence [1] - The company aims to establish an intelligent production system to meet market demands for high-quality, low-cost products, thereby enhancing its core competitiveness and maintaining its industry leadership [1]